TY - JOUR
T1 - Global Research Expedition on Altitude-related Chronic Health 2018 Iron Infusion at High Altitude Reduces Hypoxic Pulmonary Vasoconstriction Equally in Both Lowlanders and Healthy Andean Highlanders
AU - Patrician, Alexander
AU - Dawkins, Tony
AU - Coombs, Geoff B
AU - Stacey, Benjamin
AU - Gasho, Christopher
AU - Gibbons, Travis
AU - Howe, Connor A
AU - Tremblay, Joshua C
AU - Stone, Rachel
AU - Tymko, Kaitlyn
AU - Tymko, Courtney
AU - Akins, John D
AU - Hoiland, Ryan L
AU - Vizcardo-Galindo, Gustavo A
AU - Figueroa-Mujíca, Rómulo
AU - Villafuerte, Francisco C
AU - Bailey, Damian M
AU - Stembridge, Michael
AU - Anholm, James D
AU - Tymko, Michael M
AU - Ainslie, Philip N
N1 - Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Accepted manuscript in Cardiff Met's repository - https://figshare.cardiffmet.ac.uk/articles/journal_contribution/GLOBAL_REACH_2018_Iron_infusion_at_high_altitude_reduces_hypoxic_pulmonary_vasoconstriction_equally_in_both_lowlanders_and_healthy_Andean_highlanders/16919029
PY - 2021/9/8
Y1 - 2021/9/8
N2 - BACKGROUND: Increasing iron bioavailability attenuates hypoxic pulmonary vasoconstriction in both lowlanders and Sherpas at high altitude. In contrast, the pulmonary vasculature of Andeans with chronic mountain sickness (CMS) is resistant to iron administration. Although pulmonary vascular remodeling and hypertension are characteristic features of CMS, the effect of iron administration in healthy Andeans, to our knowledge, has not been investigated. If the interplay between iron status and pulmonary vascular tone in healthy Andeans remains intact, this could provide valuable clinical insight into the role of iron regulation at high altitude.RESEARCH QUESTION: Is the pulmonary vasculature in healthy Andeans responsive to iron infusion?STUDY DESIGN AND METHODS: In a double-blinded, block-randomized design, 24 healthy high-altitude Andeans and 22 partially acclimatized lowlanders at 4,300 m (Cerro de Pasco, Peru) received an IV infusion of either 200 mg of iron (III)-hydroxide sucrose or saline. Markers of iron status were collected at baseline and 4 h after infusion. Echocardiography was performed in participants during room air breathing (partial pressure of inspired oxygen [PIO2] of approximately 96 mm Hg) and during exaggerated hypoxia (PIO2 of approximately 73 mm Hg) at baseline and at 2 and 4 h after the infusion.RESULTS: Iron infusion reduced pulmonary artery systolic pressure (PASP) by approximately 2.5 mm Hg in room air (main effect, P < .001) and by approximately 7 mm Hg during exaggerated hypoxia (main effect, P < .001) in both lowlanders and healthy Andean highlanders. There was no change in PASP after the infusion of saline. Iron metrics were comparable between groups, except for serum ferritin, which was 1.8-fold higher at baseline in the Andeans than in the lowlanders (95% CI, 74-121 ng/mL vs 37-70 ng/mL, respectively; P = .003).INTERPRETATION: The pulmonary vasculature of healthy Andeans and lowlanders remains sensitive to iron infusion, and this response seems to differ from the pathologic characteristics of CMS.
AB - BACKGROUND: Increasing iron bioavailability attenuates hypoxic pulmonary vasoconstriction in both lowlanders and Sherpas at high altitude. In contrast, the pulmonary vasculature of Andeans with chronic mountain sickness (CMS) is resistant to iron administration. Although pulmonary vascular remodeling and hypertension are characteristic features of CMS, the effect of iron administration in healthy Andeans, to our knowledge, has not been investigated. If the interplay between iron status and pulmonary vascular tone in healthy Andeans remains intact, this could provide valuable clinical insight into the role of iron regulation at high altitude.RESEARCH QUESTION: Is the pulmonary vasculature in healthy Andeans responsive to iron infusion?STUDY DESIGN AND METHODS: In a double-blinded, block-randomized design, 24 healthy high-altitude Andeans and 22 partially acclimatized lowlanders at 4,300 m (Cerro de Pasco, Peru) received an IV infusion of either 200 mg of iron (III)-hydroxide sucrose or saline. Markers of iron status were collected at baseline and 4 h after infusion. Echocardiography was performed in participants during room air breathing (partial pressure of inspired oxygen [PIO2] of approximately 96 mm Hg) and during exaggerated hypoxia (PIO2 of approximately 73 mm Hg) at baseline and at 2 and 4 h after the infusion.RESULTS: Iron infusion reduced pulmonary artery systolic pressure (PASP) by approximately 2.5 mm Hg in room air (main effect, P < .001) and by approximately 7 mm Hg during exaggerated hypoxia (main effect, P < .001) in both lowlanders and healthy Andean highlanders. There was no change in PASP after the infusion of saline. Iron metrics were comparable between groups, except for serum ferritin, which was 1.8-fold higher at baseline in the Andeans than in the lowlanders (95% CI, 74-121 ng/mL vs 37-70 ng/mL, respectively; P = .003).INTERPRETATION: The pulmonary vasculature of healthy Andeans and lowlanders remains sensitive to iron infusion, and this response seems to differ from the pathologic characteristics of CMS.
KW - Andean
KW - high altitude
KW - iron
KW - pulmonary vasculatre
U2 - 10.1016/j.chest.2021.08.075
DO - 10.1016/j.chest.2021.08.075
M3 - Article
C2 - 34508740
VL - 161
SP - 1022
EP - 1035
JO - CHEST (Official publication of the American College of Chest Physicians)
JF - CHEST (Official publication of the American College of Chest Physicians)
SN - 0012-3692
IS - 4
ER -